Synthetic molecule invades double-stranded DNA

World's highest-resolution Graphene-Based OLED Screen

MeiraGTx develops next-generation gene therapies

Optogenetics may lead to cures for PTSD and Alzheimer’s

A novel silicon-based neural implant that can control the electrical activity of brain cells by shining multicolor light into the brains of awake mice has been developed by the researchers at Lawrence Livermore National Laboratory along with researchers at the University of Michigan and New York University (NYU). The technology opens new avenues for neural circuit interrogation, which will help scientists better understand the organization and function of complex neural circuits. It offers a multicolor, fiber-less solution for controlling two or more spatially intermingled neuronal populations.

5 days ago

Caribou develops new applications for CRISPR-based technologies

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. The company was founded by scientists from the University of California, Berkeley to drive the commercialization of applications based on the remarkable nucleic acid modification capabilities found in prokaryotic CRISPR systems. Caribou's proprietary technology puts scientists at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. Their singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

5 days ago

Montfort provides brain monitor and remote treatment app

Montfort develops technology designed to make the treatment of neurological disorders more efficient and effective through the use of a real-time brain monitor that is personal, inclusive, remote, and inexpensive. The company has developed a 'master app' for smartphones that link to all integral sensors, captures patients’ regular smartphone usage, analyzes the data, and sends the results to the company’s server for further analysis. These tests are Personal, Real-time, Inexpensive, and can be conducted by anyone, anywhere. The company mission is improving the health of patients who suffer from neurological disorders. By applying an inclusive and personal monitor inventors make the treatment of neurological disorders more efficient and personalized for each patient.

5 days ago

Generation Bio enables a new generation with new genetic medicines

New treatment for central nervous system disorders

A new microrobot delivers drugs in capsules

Unique and smart delivery system of medications to the brain

An innovative delivery system which increases the availability of medications at target locations and reduces their side-effects and toxicity has been developed by a team of Ben-Gurion University (BGUni) scientists. Despite great advances in therapeutic drugs, the problem of unwanted side effects remains a serious obstacle to treatment. Most adverse effects are the result of an interaction of the drugs with places in the patient’s body that are not relevant to their medicinal action.  The breakthrough system of Ben-Gurion University, called V-Smart™ drug delivery technology, is of particular interest in developing treatments of diseases that affect the central nervous system, as well as brain malignancies. 

6 days ago

Synthetic form of calcium for the treatment of a wide range of calcium-related diseases

Amorphical is a pioneering Israeli pharmaceutical company developing and manufacturing a unique form of calcium called amorphous calcium carbonate (ACC). The company is spinoff of Ben-Gurion University (BGUni). Scientists believe these new calcium-based therapeutics can become effective new tools for treating osteoporosis, hypoparathyroidism and a range of other calcium-related diseases. Inspired by the ability of the Australian Blue Crayfish to shed and regrow its exoskeleton in only three days, Amorphical scientists have demonstrated ACC’s safety, efficacy and high bioavailability, and were able to develop a proprietary synthetic form of ACC.

6 days ago

A microRNA-mediated gene therapy for spinocerebellar ataxia

Spinocerebellar ataxia (SCA) is a neurodegenerative disease characterized by progressive impairment of motor function with neuronal cell loss in the cerebellum. Over 40 causative genes have been identified in SCAs so far; however, no disease-modifying therapy is currently available. However, the research group from the University of Tokyo and the University of Chicago has developed a novel gene therapy for spinocerebellar ataxia type 6 (SCA6). SCA6 is a neurodegenerative disease affecting motor function in the patients. The researchers used a disease-specific microRNA (miRNA), a small RNA, to selectively inhibit the production of a disease-associated protein.

6 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.



100% Free of Cost For Scientists:

  • One hour of USA/EU attorney consulting
  • 24/7 support of 24 in-house professionals
  • 10 GB space for every scientist (own German Servers)
  • Syndicates with the leading professionals
  • 2,000 000 views of top spinoff are guaranteed
  • The largest DB of professional Investors - over 30.000

100% Free of Cost For Investors:

  • Investment information on 8,000+ spinoffs per year
  • All documents in one place (after NDA)
  • Testimonials from Key Opinion Leaders
  • AI-SDB hides irrelevant spinoffs - saved time up to 90% 
  • One-Click-Reports (OCRs) in own tailored design (PDF)

100% Free of Cost For Universities:

  • Professional Science Spinoff University Report (PDF)
  • No Links to - Ready to Print and Share
  • Professional dossiers on over 27Tsd VC/PE/FO/ML
  • Professional dossiers on over 3Tsd MNC